Clinical Trial Update: Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy [Phase 2]

View source ↗

Summary

Phase 2 trial of maintenance rucaparib in BRCA1/BRCA2 or PALB2 mutated pancreatic cancer after platinum-based therapy has been terminated; results posted in 202…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Rucaparib (rucaparib)

Snippet

Sponsor: Abramson Cancer Center at Penn Medicine | Conditions: Pancreatic Cancer | Phase 2 | Status: TERMINATED | Results posted: 2023-09-28